Clinical trial
Sitagliptin for the Treatment of Grade 3-4 and Refractory Acute Graft-versus-host Disease
NCT04448587 is registered in ClinicalTrials.gov with Rabin Medical Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Sitagliptin for the Treatment of Grade 3-4 and Refractory Acute Graft-versus-host Disease
- Lead sponsor
- Rabin Medical Center
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- October 1, 2020
- Completion date
- December 31, 2021
- Enrollment
- 10 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.